SAM
MYGN icon

Smartleaf Asset Management’s Myriad Genetics MYGN Stock Holding History

Smartleaf Asset Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-384
Closed -$2.02K – 3048
2025
Q2 		$2.02K Sell
384
-38
-9% -$224 ﹤0.01% 2334
2025
Q1 		$3.75K Sell
422
-682
-62% -$8.19K ﹤0.01% 2282
2024
Q4 		$15K Buy
1,104
+721
+188% +$13.3K ﹤0.01% 1805
2024
Q3 		$10.1K Buy
383
+197
+106% +$5.33K ﹤0.01% 1752
2024
Q2 		$4.52K Buy
186
+12
+7% +$263 ﹤0.01% 1852
2024
Q1 		$3.72K Buy
+174
New +$3.74K ﹤0.01% 1314

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Smartleaf Asset Management's MYGN Position: Q3 2025 in Review

Smartleaf Asset Management sold out of Myriad Genetics (MYGN) in Q3 2025, closing a stake of 384 shares — an estimated $2.02K sold.

Smartleaf Asset Management first reported a position in MYGN in Q1 2024 and held it in 6 quarters. The position peaked at $15K in Q4 2024. 221 funds tracked by Wall St. Rank hold MYGN as of Q3 2025.

  • Smartleaf Asset Management reported no remaining Myriad Genetics position as of Q3 2025 after selling out during the quarter.
  • Smartleaf Asset Management sold 384 Myriad Genetics shares in Q3 2025, an estimated $2.02K.
  • Smartleaf Asset Management first reported a position in Myriad Genetics in Q1 2024 and held it in 6 quarters.
  • Smartleaf Asset Management's Myriad Genetics position peaked at $15K in Q4 2024.
  • 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2025.

Based on Smartleaf Asset Management's 13F filing for Q3 2025, filed 5 Nov 2025.